ERN ReCONNET-SLICC-SLEuro consensus on the therapeutic management of rare systemic lupus erythematosus manifestations (part 2).

Authors

Laurent Arnaud, Odirlei A Monticielo, Matteo Piga, Nathalie Costedoat-Chalumeau, Zahi Touma, Guillermo Ruiz-Irastorza, Sang-Cheol Bae, Sasha Bernatsky, Eloisa Bonfa, Francesca Bottazzi, Ricard Cervera, Gamal Chehab, Ann E Clarke, Maria Dall'era, Alí Duarte-Garcia, Gerard Espinosa, Paul R Fortin, Micaela Fredi, José A Gómez-Puerta, Shinji Izuka, Andreas Jönsen, Nikita Khmelinskii, Alexandra Legge, Sandra Meisalu, Luca Moroni, Giovanni Orsolini, Ivan Padjen, Michelle Petri, Guillermo Pons-Estel, Giuseppe A Ramirez, Rosalind Ramsey-Goldman, Savino Sciascia, Angela Tincani, Massimo Triggiani, Manuel F Ugarte-Gil, Evelyne Vinet, Edward M Vital, Marta Mosca, Chiara Tani, ERN ReCONNET–SLICC–SLEuro rare SLE taskforce member panel

Published in

The Lancet. Rheumatology. Aug 26, 2026. Epub Aug 26, 2026.

Abstract

Systemic lupus erythematosus (SLE) guidelines predominantly focus on common major organ involvement. An international taskforce from three SLE expert groups (European Reference Network on Connective Tissue and Musculoskeletal Diseases, Systemic Lupus International Collaborating Clinics, and the European Lupus Society) previously developed consensus therapeutic strategies for 24 rare SLE manifestations. Here, 77 participants contributed to the development of consensus therapeutic strategies for 22 additional rare SLE manifestations, including diffuse pulmonary haemorrhage, rare cutaneous manifestations (bullous lupus, chilblain lupus, lupus tumidus, erythema multiforme, and toxic epidermal necrolysis-like lupus erythematosus), renal manifestations (interstitial nephritis and lupus podocytopathy), rare neurological manifestations (chorea, small fibre neuropathy, catatonia, and intracranial hypertension), rare gastrointestinal manifestations (protein-losing enteropathy, lupus hepatitis, intestinal pseudo-obstruction, and peritonitis), musculoskeletal manifestations (myositis and Jaccoud's arthropathy), and other rare manifestations such as uveitis, angioedema due to anti-C1 esterase inhibitor antibodies, interstitial cystitis, and lupus mastitis. These expert-based therapeutic strategies provide a framework for guiding therapeutic decisions where evidence-based recommendations might be insufficient.

PMID:
42648304
Bibliographic data and abstract were imported from PubMed on 27 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.